Loading organizations...
Key people at Oncopeptides AB.
Oncopeptides AB is a biotech company focused on researching, developing, and commercializing targeted therapies for difficult-to-treat cancers. The firm specializes in innovative drug candidates for haematological diseases, leveraging advanced technological platforms. Their precision medicine approach addresses unmet oncology needs by targeting specific disease mechanisms.
Professor Hans Ehrsson and Peter Nygren, alongside leading Swedish researchers, founded Oncopeptides. Their combined expertise in analytical chemistry, clinical pharmacology, and oncology drove the insight for novel therapeutic strategies. This led to developing peptide-drug conjugates for selective delivery of cytotoxic agents to cancer cells, aiming for improved efficacy.
Oncopeptides serves patients with challenging cancers, particularly haematological malignancies, where treatment options are often inadequate. The company’s vision is to provide transformative drugs, offering new hope and improved lives through dedicated scientific innovation. They commit to translating research into meaningful clinical impact for these populations.
Key people at Oncopeptides AB.
Oncopeptides AB (publ) is a Stockholm-based biotechnology company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological cancers, particularly relapsed refractory multiple myeloma.[1][2] Its lead product, Pepaxti (melflufen), a Peptide Drug Conjugate (PDC) approved in Europe, targets adult patients with multiple myeloma by exploiting cancer cells' altered metabolism to deliver cytotoxic payloads selectively.[1][2] The company serves patients with unmet needs in oncology, solving challenges in treating resistant cancers through its PDC and SPiKE platforms, with a pipeline including OPD5, OPDC3, Gliopep for hematological/solid tumors and glioblastoma, and SPiKE for NK-cell engagement.[1][2] With 75-80 employees and headquarters in Stockholm, Oncopeptides demonstrates growth through full European approval of its first drug and ongoing pipeline advancement.[1][2]
Oncopeptides AB was founded in 2000 by Sweden's leading cancer researchers and institutions to develop anti-cancer drugs, starting with melflufen, which gained patent protection that year.[2][3] Early preclinical development (2003-2009) was financed by Industrifonden and Karolinska Development AB, leading to Phase 1 studies in solid tumors at Uppsala University Hospital and a key U.S. collaboration with Harvard Medical School–Dana-Farber Cancer Institute in 2009-2011, including a new freeze-dried formulation.[3] Pivotal investments from 2012-2013 by HealthCap, Industrifonden, and others funded Phase 1/2 trials in multiple myeloma; by 2017, the company went public on Nasdaq Stockholm (ticker: ONCO), launched the Phase 3 OCEAN and Phase 2 HORIZON studies, and secured patents until 2032.[1][3] This evolution from research spinout to commercial-stage biotech humanizes its mission-driven focus on patient access to innovative alkylating drugs after 25 years of development.[2][3]
Oncopeptides stands out in oncology biotech through:
Oncopeptides rides the wave of precision oncology and antibody-drug conjugate (ADC) evolution, where targeted therapies address unmet needs in hematological malignancies amid rising multiple myeloma incidence and resistance to standard treatments like CAR-T and proteasome inhibitors.[1][2] Timing aligns with post-2020 regulatory accelerations for novel conjugates, bolstered by European approval and U.S. pursuits, amid market forces favoring platforms like PDC/SPiKE for their tumor-selective delivery over traditional chemotherapies.[1][3] It influences the ecosystem by validating Swedish biotech innovation, fostering U.S.-Europe collaborations (e.g., Dana-Farber), and contributing to the global shift toward metabolism-exploiting drugs, potentially expanding to solid tumors.[2][3]
Oncopeptides is poised for pipeline expansion with PDC/SPiKE candidates advancing toward clinical readouts, U.S. commercialization of Pepaxti, and potential partnerships leveraging its 2032 patents.[1][3] Trends like AI-accelerated drug design and combination therapies for myeloma will shape its path, amplifying influence if OCEAN/HORIZON data sustain survival benefits.[3] Evolving from a research pioneer to a transformative player, it exemplifies resilient biotech grit in delivering hope through targeted innovation—much like its founding vision amid oncology's toughest challenges.[2]
